Physician profile
Anna Chacon
NPI 1073950689
$8,052.67
in general payments reported to CMS, 2019-2025
31 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,097 · 2020: $311 · 2021: $1,002 · 2022: $1,155 · 2023: $118 · 2024: $132 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,875 · Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,875.00 |
| Food and Beverage | $612.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $1,875.00 | 2025 | Olumiant |
| Allergan, INC. | $984.00 | 2019 | |
| Teladoc Health, INC. | $800.00 | 2022 | |
| Genzyme Corporation | $651.22 | 2019-2021 | |
| Viiv Healthcare Company | $432.83 | 2019-2022 | |
| Abbvie INC. | $390.65 | 2019-2025 | |
| Celgene Corporation | $382.86 | 2019 | |
| Sun Pharmaceutical Industries INC. | $357.31 | 2019-2020 | |
| Galderma Laboratories, L.P. | $327.98 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $299.36 | 2019-2021 | |
| Amgen INC. | $278.21 | 2020-2025 | Otezla |
| Sentynl Therapeutics, INC. | $267.00 | 2021 | |
| Organon LLC | $186.06 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $120.74 | 2023-2024 | Tremfya |
| Janssen Biotech, INC. | $111.76 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $92.82 | 2019 | |
| Pfizer INC. | $82.70 | 2020-2022 | |
| Dusa Pharmaceuticals, INC. | $68.95 | 2019 | |
| Epi Health, LLC | $58.82 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.77 | 2022 | |
| Incyte Corporation | $42.88 | 2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $37.26 | 2019 | |
| Verrica Pharmaceuticals INC. | $25.21 | 2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $23.28 | 2023 | Sotyktu |
| Genentech USA, INC. | $22.97 | 2020 | |
| Arcutis Biotherapeutics, INC. | $19.20 | 2023 | |
| Dermavant Sciences, INC. | $18.77 | 2024 | Vtama |
| Merz North America, INC. | $15.40 | 2020 | |
| Journey Medical Corporation | $14.84 | 2022 | |
| Leo Pharma INC. | $10.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Chacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.